BioB, using the JUPITER trial results as an indication of Vascepa's success would be inaccurate. First of all, the JUPITER trial was for a Statin, statins have the ability to lower LDL while raising HDL and they also lower hsCRP, an inflammatory biomarker. So you cannot compare a Statin nor its results with EPA. If anything, the truest clinical trial comparison that one can use for Vascepa is the trial called JELIS, go look it up.
Market Data 
Markets 
AI
